The Association of Biotechnology Companies BioForum would like to invite you to a conference aimed at discussing the impact of the EU Pharmaceutical Package on the health care sector in Poland.
WHAT ARE WE GOING TO TALK ABOUT?
Is moving away from the “one size fits all” model, modulating and shortening data exclusivity periods (RDP) an idea adequate to the needs?
What should modern machismos for supporting innovation in pharmacy look like – what legal conditions do companies from the pharmaceutical sector need to develop and be able to compete on global markets?
What are the problems and possible solutions aimed at strengthening drug safety and stimulating the growth of the health care sector in Poland – are the new obligations of pharmaceutical companies adequate to the current needs and do we need new incentives to invest in the health sector in Poland?
SPEAKERS:
- Joanna Krakowiak – Wardyński & Partners
- Vlad Oltenau – EuropaBio
- Adrian Van Den Hoven – Medicines for Europe
MODERATORS:
- Jakub Styczyński – Rynekzdrowia.pl
- Joanna Krakowiak – Wardyński & Partners
DEBATE PARTICIPANTS:
- Marlena Tryka – Ministry of Development and Technology
- Wojciech Nowak – Novartis
- Oleg Siarkevych – BioForum expert
- Grzegorz Rychwalski – PZPPF KPP
- Sędzimir Chmurzyński – Adamed
GOAL OF THE EVENT:
Discussion on the impact of the EU Pharmaceutical Package on the healthcare sector in Poland, in particular:
- Mechanisms to stimulate the innovation of the sector, in particular R&D works, in the context of financing innovations and protecting innovative products entering the market,
- Stimulating medical investments in Poland and in the region, in particular in terms of strengthening the region’s drug safety and stimulating the growth of the pharmaceutical and biotechnology sectors as important branches of the modern economy.
Exchange of views of representatives of various environments and stakeholders in the course of EU legislative work on the draft Pharmaceutical Package.
Obtaining information on the current status of legislative work and possible scenarios for the future as well as the probable calendar of further events.
Popularization of legal regulations concerning the pharmaceutical market and biotechnology.
Building the position of event partners as leading advisors in the industry.